EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)VergleichsstudieOpen Access · CC BY-NC-ND 4.0

Comparison of pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a candidate biosimilar INTP23.1 with EU and US‑approved denosumab reference products in healthy adult men

Steve Fenwick iD, Vidhi Parekh, Naman Shah, Ronak Patel, Prashant Kale, Shrikrishna Kolte

Naunyn-Schmiedeberg's Archives of Pharmacology · 2026

DOI: 10.1007/s00210-025-04964-5 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2026. Verfasst von Steve Fenwick und 5 weiteren Autor:innen. Beteiligte Einrichtung: Accord Healthcare Ltd, Sage House, 319 Pinner Road, North Harrow, Middlesex, HA1 4HF, UK. Steven_Fenwick@Accord-Healthcare.com. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Denosumab, Bone Density Conservation Agents. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: This Phase 1 study evaluated the pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and safety of INTP23.1, a proposed denosumab biosimilar, compared with US- and EU-licensed reference denosumab (Xgeva®) in healthy male volunteers. METHODS: This randomized, double-blind, three-arm, 36 week, parallel-group trial (CTRI/2020/09/027619), assessed a single 35 mg subcutaneous dose of INTP23.1, Xgeva (US), or Xgeva (EU), administered in the upper arm. PK endpoints were statistically compared using geometric least-squares means (LSM) and 90% confidence intervals (CIs). PD markers were evaluated, immunogenicity and safety were assessed through validated assays, and adverse events (AEs) were monitored. RESULTS: A total of 234 healthy male volunteers were enrolled. Baseline demographics were similar across the three treatment sequence groups. PK equivalence was demonstrated, with all geometric LSM ratios and 90% CIs for maximum serum concentration, area under the concentration-time curve (AUC) from time zero to the last measurable concentration, and AUC from time zero to infinity falling within the predefined bioequivalence range of 80.00% to 125.00%. PD responses showed comparable suppression of C-terminal telopeptide (CTX) and procollagen type 1 N-terminal propeptide (P1NP) across treatment groups. Immunogenicity profiles were similar, with low anti-drug antibody incidence and no neutralizing antibodies detected. AEs were generally mild or moderate in intensity, and no unexpected safety signals were observed. CONCLUSIONS: INTP23.1 demonstrated comparable PK, PD, immunogenicity, and safety to US- and EU-licensed denosumab reference products in healthy male volunteers. These findings support further clinical development of INTP23.1 as a denosumab biosimilar for approved indications. TRIAL REGISTRATION NUMBER: CTRI/2020/09/027619; Registered 07/09/2020.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biosimilar PharmaceuticalsDenosumabBone Density Conservation AgentsHumansMaleAdultDouble-Blind MethodYoung AdultTherapeutic EquivalencyHealthy VolunteersMiddle AgedProcollagenCollagen Type IAdolescentPeptide Fragments

Stichwörter der Autor:innen

BiosimilarDenosumabImmunogenicityOsteoporosisPharmacodynamicsPharmacokinetics

Substanzen

Biosimilar PharmaceuticalsDenosumabBone Density Conservation AgentsProcollagenCollagen Type Iprocollagen Type I N-terminal peptidePeptide Fragments

Autor:innen und Institutionen

  • Accord Healthcare Ltd, Sage House, 319 Pinner Road, North Harrow, Middlesex, HA1 4HF, UK. Steven_Fenwick@Accord-Healthcare.com.
  • Intas Pharmaceuticals Ltd., Corporate House, 2nd Floor, C-Wing, Nr. Sola Bridge, S. G. Highway, Thaltej, Ahmedabad, 380054, Gujarat, India.
  • Lambda Therapeutic Research Limited, Lambda House, Plot No.38, S.G. Highway, Gota, Ahmedabad, 382 481, Gujarat, India.

ORCID-Profile: Steve Fenwick

Zitieren

APA

Fenwick, S., Parekh, V., Shah, N., Patel, R., Kale, P., & Kolte, S. (2026). Comparison of pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a candidate biosimilar INTP23.1 with EU and US‑approved denosumab reference products in healthy adult men. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-025-04964-5

Vancouver

Fenwick S, Parekh V, Shah N, Patel R, Kale P, Kolte S. Comparison of pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a candidate biosimilar INTP23.1 with EU and US‑approved denosumab reference products in healthy adult men. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-025-04964-5

BibTeX
@article{Fenwick2026,
  author = {Fenwick, Steve and Parekh, Vidhi and Shah, Naman and Patel, Ronak and Kale, Prashant and Kolte, Shrikrishna},
  title = {Comparison of pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a candidate biosimilar INTP23.1 with EU and US‑approved denosumab reference products in healthy adult men},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2026},
  doi = {10.1007/s00210-025-04964-5}
}
Kostenlos starten →